Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 Ready to Announce with Confidence?

newsfilecorp.com

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 Ready to Announce with Confidence? Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, April 14 at Nasdaq in New York City.

Christer Rosén, Chairman and CEO will discuss the Company's recent performance and future growth plans.

The Centri Capital Conference will gather attendees from across the capital markets ecosystem and investment community, including investment bankers, private equity investors, family offices, and high-net-worth individuals. The highly anticipated conference will feature company presentations and fireside chats, facilitated investor 1:1 meetings, and panel discussions featuring insights from thought leaders in the capital markets space.

Jupiter Neurosciences, Inc. joins a distinguished list of exciting and disruptive presenting companies like Grayscale, Orchestra BioMed, CoinShares, ReserveOne, MVB Financial and many others. Also included in the event at Nasdaq are key sponsors in the capital markets space, including Morgan Stanley, DFIN, Chardan, Gusto, CBIZ, ICR and The Money Channel.

"The companies involved with the Centri Capital Conference embody the innovation and diversity shaping today’s capital markets,” says Michael Aiello, CEO & Managing Partner of Centri. “We are excited to welcome them to Nasdaq for investor 1:1 meetings and meaningful exchanges with leaders from across the industry."

Companies and investors interested in presenting, attending, or sponsoring the Centri Capital Conference can learn more here: www.CentriConsulting.com/capital-conference.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability in clinical studies. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

About Centri Business Consulting, LLC

Centri Business Consulting provides the highest quality advisory consulting services to its clients by being reliable and responsive to their needs. Centri provides companies with the expertise they need to meet their reporting demands. Centri specializes in financial reporting, internal controls, technical accounting research, valuation, mergers & acquisitions, and tax, CFO and HR advisory services for companies of various sizes and industries. From complex technical accounting transactions to monthly financial reporting, our professionals can offer any organization the specialized expertise and multilayered skillsets to ensure the project is completed timely and accurately.

For additional Information, please contact:

Jupiter Neurosciences, Inc.

Christer Rosén

(561) 406-6154

ir@jupiterneurosciences.com

https://jupiterneurosciences.com/

Source: Centri

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Centri or all companies in the Banking / Financial Services industry.

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

2026-04-13 8:00 PM EDT

Giftpack to Present at Centri Capital Conference on April 14

2026-04-13 9:00 AM EDT

Reliance Global Group to Participate in Centri Capital Conference at Nasdaq MarketSite in New York City on April 14, 2026

2026-04-10 8:30 AM EDT

Jul 29, 2025

Here’s what we’ve learned from over 200,000 regulatory filings—and how you can apply it: For the 200+ Canadian companies also listed in the United States, the stakes for regulatory compliance have never been higher. A single filing error can trigger significant stock price volatility and lead to major financial and reputational damage. SEDAR+ and EDGAR process thousands of filings every day. In just its first three months, SEDAR+ handled over 30,000 disclosures. EDGAR, meanwhile, processes...

Economy, Business and Finance

Energy and Resource

Energy (general)

Banking / Financial Services